Contact
searchSearch
HMP Global
Login
Quiz

Test Your Knowledge—Digital Therapeutics: A Different Treatment Modality for ADHD

04/23/2026

Related Content

Julie Carbray, PhD, PMHNP-BC, and James Greenblatt, MD
Videos
First-Line Decisions in ADHD: Lifestyle Modification or Medication?
09/18/2026
Julie Carbray PhD, PMHNP-BC, PMHCNS-BC, APRN; James Greenblatt, MD
Julie Carbray, PhD, PMHNP-BC, FAAN, and James Greenblatt, MD, discuss how functional impairment, symptom severity, patient preferences, life stage, and family perspectives can shape initial ADHD treatment decisions, as explored at their 2026...
Julie Carbray, PhD, PMHNP-BC, FAAN, and James Greenblatt, MD, discuss how functional impairment, symptom severity, patient preferences, life stage, and family perspectives can shape initial ADHD treatment decisions, as explored at their 2026...
Julie Carbray, PhD, PMHNP-BC,...
09/18/2026
Psych Congress Network
a physician reviews data on a tablet
Conference Preview
Guiding Clinicians Through Psychiatry’s Next Era at Psych Congress 2026
09/14/2026
Maria Mantas
As psychiatry rapidly evolves, the 39th annual Psych Congress promises to prepare clinicians for the changing landscape of patient care.
As psychiatry rapidly evolves, the 39th annual Psych Congress promises to prepare clinicians for the changing landscape of patient care.
As psychiatry rapidly evolves,...
09/14/2026
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, MSN, APRN, PMHNP-BC
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Insights
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Desiree Matthews, PHMNP-BC; Amber Hoberg, MSN, APRN, PMHNP-BC
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use